PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. Bacteria are back. Following the discovery and introduction into medicine of penicillin in 1941, intense research in microbiology produced a potent armament of antibiotics that all but eliminated a variety of infectious diseases. With this success, many large pharmaceutical companies scaled back research and development of new
 PHASE III NEARS: Cubist Pharmaceuticals has a promising antibiotic--daptomycin--that the company hopes to have in Phase III clinical trials in late 1998 or early 1999. |
Data collected by the Synercid Microbiology Assessment of Resistance Trends (SMART)--a surveillance project run by the State University of New York (SUNY) at Buffalo and the University of Iowa College of Medicine--show increasing drug resistance in the United States. More than 31 percent of 17,000 bacterial isolates ...
These fluttering sensations are the brain’s reaction to certain emotions, which can be amplified or soothed by the gut’s own “bugs".
View this Issue
Olga Anczukow and Ryan Englander discuss how transcriptome splicing affects immune system function in lung cancer.
In our next roundtable webinar, learn how scientists leverage spatial biology to map tissues, uncover cellular interactions, and advance disease research.
Discover how scientists use the latest gene editing tools to advance health research.
Fujirebio's Lumipulse® G pTau217/β-Amyloid 1-42 Plasma Ratio test has the potential to shorten the Alzheimer's disease diagnostic journey and enable earlier intervention through its accessibility and high diagnostic performance.
Ten-year Agreement to Provide a Secure, AI-enabled Forensic Laboratory Information Management System Supporting DHS Forensic, Scientific, and Testing Services
deliver robust, reproducible solutions for sample preparation enabling a new era of end-to-end standardization in proteomics
Enables higher-throughput, cost effective single-cell sequencing
Enables ultra-low variant detection across a range of key MRD targets in AML, including very large FLT3-ITDs
